Mark L. Brader

1.8k total citations
33 papers, 1.3k citations indexed

About

Mark L. Brader is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark L. Brader has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark L. Brader's work include Protein purification and stability (12 papers), Metal complexes synthesis and properties (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Mark L. Brader is often cited by papers focused on Protein purification and stability (12 papers), Metal complexes synthesis and properties (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Mark L. Brader collaborates with scholars based in United States, New Zealand and Denmark. Mark L. Brader's co-authors include Michael F. Dunn, Lin Jin, Niels C. Kaarsholm, Jessica M. Banks, Allen H. Pekar, Pavel Landsman, Z. Hong Zhou, Sean Williams, Wong H. Hui and Roy W. Alston and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Nature Biotechnology.

In The Last Decade

Mark L. Brader

33 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark L. Brader United States 20 914 263 233 128 125 33 1.3k
Ricardo J. Solá Puerto Rico 15 1.1k 1.2× 342 1.3× 266 1.1× 95 0.7× 146 1.2× 15 1.9k
Leonard M. Thomas United States 19 662 0.7× 148 0.6× 441 1.9× 166 1.3× 81 0.6× 50 1.8k
Devkumar Mustafi United States 20 343 0.4× 185 0.7× 163 0.7× 130 1.0× 72 0.6× 74 1.1k
Karim Elbayed France 23 447 0.5× 245 0.9× 140 0.6× 36 0.3× 432 3.5× 63 1.2k
Jarkko Valjakka Finland 19 813 0.9× 136 0.5× 124 0.5× 77 0.6× 34 0.3× 39 1.3k
Carsten Behrens Denmark 14 2.3k 2.5× 149 0.6× 103 0.4× 69 0.5× 49 0.4× 25 2.6k
Motoharu Iwatsuru Japan 23 1.3k 1.4× 258 1.0× 150 0.6× 139 1.1× 62 0.5× 63 2.1k
P Poučková Czechia 24 728 0.8× 109 0.4× 510 2.2× 204 1.6× 63 0.5× 102 1.9k
Allen H. Pekar United States 16 891 1.0× 199 0.8× 175 0.8× 40 0.3× 150 1.2× 22 1.2k
Athanasios Galanis Greece 15 458 0.5× 134 0.5× 187 0.8× 199 1.6× 43 0.3× 38 980

Countries citing papers authored by Mark L. Brader

Since Specialization
Citations

This map shows the geographic impact of Mark L. Brader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. Brader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. Brader more than expected).

Fields of papers citing papers by Mark L. Brader

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark L. Brader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. Brader. The network helps show where Mark L. Brader may publish in the future.

Co-authorship network of co-authors of Mark L. Brader

This figure shows the co-authorship network connecting the top 25 collaborators of Mark L. Brader. A scholar is included among the top collaborators of Mark L. Brader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark L. Brader. Mark L. Brader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kloczewiak, Marek, Jessica M. Banks, Lin Jin, & Mark L. Brader. (2022). A Biopharmaceutical Perspective on Higher-Order Structure and Thermal Stability of mRNA Vaccines. Molecular Pharmaceutics. 19(7). 2022–2031. 59 indexed citations
2.
Brader, Mark L., Sean Williams, Jessica M. Banks, et al.. (2021). Encapsulation state of messenger RNA inside lipid nanoparticles. Biophysical Journal. 120(14). 2766–2770. 160 indexed citations
3.
Brader, Mark L., Edward N. Baker, Michael F. Dunn, Thomas M. Laue, & John F. Carpenter. (2016). Using X-Ray Crystallography to Simplify and Accelerate Biologics Drug Development. Journal of Pharmaceutical Sciences. 106(2). 477–494. 19 indexed citations
4.
Temel, Deniz B., Pavel Landsman, & Mark L. Brader. (2015). Orthogonal Methods for Characterizing the Unfolding of Therapeutic Monoclonal Antibodies. Methods in enzymology on CD-ROM/Methods in enzymology. 567. 359–389. 65 indexed citations
5.
Bai, Shujun, Pavel Landsman, Andrea E. Spencer, et al.. (2015). Evaluation of Incremental Siliconization Levels on Soluble Aggregates, Submicron and Subvisible Particles in a Prefilled Syringe Product. Journal of Pharmaceutical Sciences. 105(1). 50–63. 14 indexed citations
6.
Brader, Mark L., et al.. (2013). Monitoring protein aggregation kinetics with simultaneous multiple sample light scattering. Analytical Biochemistry. 437(2). 185–197. 28 indexed citations
7.
Bai, Shujun, et al.. (2012). Effects of Submicron Particles on Formation of Micron-Sized Particles During Long-Term Storage of an Interferon-Beta-1a Solution. Journal of Pharmaceutical Sciences. 102(2). 347–351. 9 indexed citations
8.
Li, Hao, et al.. (2011). Calcium Binding to a Factor IX Fc Fusion Protein and Effects on Higher‐Order Structure. Journal of Pharmaceutical Sciences. 100(11). 4597–4606. 3 indexed citations
9.
Gabrielson, John P., Mark L. Brader, Allen H. Pekar, et al.. (2006). Quantitation of Aggregate Levels in a Recombinant Humanized Monoclonal Antibody Formulation by Size-Exclusion Chromatography, Asymmetrical Flow Field Flow Fractionation, and Sedimentation Velocity. Journal of Pharmaceutical Sciences. 96(2). 268–279. 127 indexed citations
10.
Doyle, Brandon L., et al.. (2005). Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: A prototypical example of biopharmaceutical aggregation. Journal of Pharmaceutical Sciences. 94(12). 2749–2763. 6 indexed citations
11.
Yip, Christopher M., Mark L. Brader, Bruce H. Frank, Michael R. DeFelippis, & Michael D. Ward. (2000). Structural Studies of a Crystalline Insulin Analog Complex with Protamine by Atomic Force Microscopy. Biophysical Journal. 78(1). 466–473. 22 indexed citations
12.
Pekar, Allen H., et al.. (1998). Effects of Non-Covalent Self-Association on the Subcutaneous Absorption of a Therapeutic Peptide. Pharmaceutical Research. 15(2). 254–262. 43 indexed citations
13.
Yip, Christopher M., Michael R. DeFelippis, Bruce H. Frank, Mark L. Brader, & Michael D. Ward. (1998). Structural and Morphological Characterization of Ultralente Insulin Crystals by Atomic Force Microscopy: Evidence of Hydrophobically Driven Assembly. Biophysical Journal. 75(3). 1172–1179. 41 indexed citations
14.
Brader, Mark L., Niels C. Kaarsholm, Sven E. Harnung, & Michael F. Dunn. (1997). Ligand Perturbation Effects on a Pseudotetrahedral Co(II)(His)3-Ligand Site. Journal of Biological Chemistry. 272(2). 1088–1094. 21 indexed citations
15.
Radziuk, J., Henry A. Havel, Mark L. Brader, et al.. (1996). Physicochemical basis for the rapid time‐action of LysB28ProB29‐insulin: Dissociation of a protein‐ligand complex. Protein Science. 5(12). 2521–2531. 67 indexed citations
16.
Brader, Mark L., et al.. (1993). Allosteric transition of the insulin hexamer is modulated by homotropic and heterotropic interactions. Biochemistry. 32(43). 11638–11645. 33 indexed citations
17.
Brader, Mark L., Dan Borchardt, & Michael F. Dunn. (1992). The T to R transition in the copper(II)-substituted insulin hexamer. Anion complexes of the R-state species exhibiting type 1 and type 2 spectral characteristics. Biochemistry. 31(19). 4691–4696. 12 indexed citations
18.
19.
Ainscough, Eric W., Edward N. Baker, Mark L. Brader, et al.. (1991). Synthetic, spectroscopic and X-ray crystallographic studies on phenylcyanamidocopper(I) complexes. Journal of the Chemical Society Dalton Transactions. 1243–1243. 24 indexed citations
20.
Brader, Mark L., Niels C. Kaarsholm, & Michael F. Dunn. (1990). The R-state proinsulin and insulin hexamers mimic the carbonic anhydrase active site.. Journal of Biological Chemistry. 265(26). 15666–15670. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ricardo J. Solá Breakdown of academic impact, for papers by Leonard M. Thomas Breakdown of academic impact, for papers by Devkumar Mustafi Breakdown of academic impact, for papers by Karim Elbayed Breakdown of academic impact, for papers by Jarkko Valjakka Breakdown of academic impact, for papers by Carsten Behrens Breakdown of academic impact, for papers by Motoharu Iwatsuru Breakdown of academic impact, for papers by P Poučková Breakdown of academic impact, for papers by Allen H. Pekar Breakdown of academic impact, for papers by Athanasios Galanis
Rankless by CCL
2026